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The authors of the published paper [1] would like to correct Table 1. The sixth row in the
second column should have been Amphotericin B Lipid Complex (ABLC). Therefore, Table 1 should
read as follows:
Table 1. Treatment recommendations for invasive aspergillosis.
Recommendation Drug Dosing Comments
Primary Voriconazole 6 mg/kg IV every 12 h timestwo then 4 mg/kg IV every 12 h
Oral therapy at mg/kg
dosing or 200–300 mg
every 12 h; TDM required
Alternatives
Lipsosomal
amphotericin B
(L-AMB)
3–5 mg/kg/day IV
Isavuconazole 200 mg every 8 h IV or PO timessix then 200 mg daily IV or PO
Need for TDM
remains undefined
Voriconazole plus
Anidulafungin
Vorizonazole as above plus
Anidulafungin 200 mg IV daily
times one then 100 mg IV daily
Combination therapy
considered in severe disease
and with hematologic
malignancy
Amphotericin B Lipid
Complex (ABLC) 5 mg/kg/day IV
Secondary Caspofungin 70 mg IV daily times one then50 mg IV daily Monotherapy as salvage
Posaconazole
Oral suspension: 200 mg PO
every 8 h, Tablet: 300 mg PO
every 12 h times two then
300 mg PO daily, Intravenous:
300 mg IV every 12 h
times two then 300 mg IV daily
Caution in use of tablet
formulation with acid
suppression; TDM required
Itraconazole 200 mg PO every 12 h TDM required
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We apologize for any inconvenience caused to readers. The manuscript will be updated and the
original will remain available on the article webpage.
Conflicts of Interest: The authors declare no conflict of interest.
Reference
1. Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the
Evidence. J. Fungi 2016, 2, 25. [CrossRef]
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
